Skip to main content

Part of Cancer staging guidance sheets

Testis tumours (ICD10 C62)

Previous Chapter

Prostate tumours

Current Chapter

Current chapter – Testis tumours (ICD10 C62)

View all

Next Chapter

Kidney tumours

Page contents

Introduction

This is the data sheet for TNM 9th edition staging of testis tumours (ICD10 C62).

For more detailed information regarding TNM staging, please see pages 190-193 of the UICC TNM 9 book.

Stage groupings

Stage Group

T stage

N stage

M stage

Serum markers

Stage 0

pTis

N0

M0

S0

Stage I

pT1–T4

N0

M0

SX

Stage IA

pT1

N0

M0

S0

Stage IB

pT2–T4

N0

M0

S0

Stage IS

Any pT/TX

N0

M0

S1 – S3

Stage II

Any pT/TX

N1 – N3

M0

SX

Stage IIA

Any pT/TX

N1

M0

S0

 

Any pT/TX

N1

M0

S1

Stage IIB

Any pT/TX

N2

M0

S0

 

Any pT/TX

N2

M0

S1

Stage IIC

Any pT/TX

N3

M0

S0

 

Any pT/TX

N3

M0

S1

Stage III

Any pT/TX

Any N

M1a

SX

Stage IIIA

Any pT/TX

Any N

M1a

S0

 

Any pT/TX

Any N

M1a

S1

Stage IIIB

Any pT/TX

N1–N3

M0

S2

 

Any pT/TX

Any N

M1a

S2

Stage IIIC

Any pT/TX

N1–N3

M0

S3

 

Any pT/TX

Any N

M1a

S3

 

Any pT/TX

Any N

M1b

Any S

TNM clinical classification

T - primary tumour

Except for pTis and pT4, where radical orchiectomy is not always necessary for classification purposes, the extent of the primary tumour is classified after radical orchiectomy; see pT. In other circumstances, TX is used if no radical orchiectomy has been performed.

N - regional lymph nodes

N value

Description

cNX

Regional lymph nodes cannot be assessed

cN0

No regional lymph node metastasis

cN1

Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension

cN2

Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension

cN3

Metastasis with a lymph node mass more than 5 cm in greatest dimension

M - distant metastasis

M value

Description

M0

No distant metastasis

M1

Distant metastasis

M1a - Non‐regional lymph node(s) or lung metastasis

M1b - Distant metastasis other than non‐regional lymph nodes and lung

TNM pathological classification

pT - primary tumour

pT value

Description

pTX

Primary tumour cannot be assessed (see T – Primary Tumour)

pT0

No evidence of primary tumour (e.g., histological scar in testis)

pTis

Intratubular germ cell neoplasia (carcinoma in situ)

pT1

Tumour limited to testis, including the rete testis, but without vascular/lymphatic invasion or invasion of the epididymis; tumour may invade tunica albuginea but not tunica vaginalis1

pT2

Tumour limited to testis with vascular/lymphatic invasion, or invading hilar soft tissue or epididymis or tumour extending through tunica albuginea with involvement of tunica vaginalis

pT3

Tumour invades spermatic cord with or without vascular/lymphatic invasion2

pT4

Tumour invades scrotum with or without vascular/lymphatic invasion

Note: 

1 AJCC subdivides pT1 seminoma into pT1a and pT1b depending on size no greater than 3 cm or greater than 3 cm in greatest dimension

2 AJCC notes that discontinuous involvement of spermatic cord should be considered as M1

pN - regional lymph nodes

pN value

Description

pNX

Regional lymph nodes cannot be assessed

pN0

No regional lymph node metastasis

pN1

Metastasis with a lymph node mass 2 cm or less in greatest dimension and five or fewer positive nodes, not more than 2 cm in greatest dimension

pN2

Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than five nodes positive, not more than 5 cm; or evidence of extranodal extension of tumour

pN3

Metastasis with a lymph node mass more than 5 cm in greatest dimension

 

Definition of serum markers

S category

S criteria

SX

Serum marker studies not available or not performed

S0

Serum marker study levels within normal limits

 

S category

LDH

hCG (mIU/ml)

AFP (ng/ml)

S1

<1.5 x N

and <5000

and <1000

S2

1.5 - 10 x N

or 5000 - 50 000

or 1000 - 10 000

S3

>10 x N

or >50 000

or >10 000

Note

N indicates the upper limit of normal for the LDH assay

Download

Click on the box below to download a PDF version of this staging sheet:

Last edited: 16 January 2026 3:52 pm

Previous Chapter

Prostate tumours

Next Chapter

Kidney tumours
  1. Cancer staging guidance sheets
  2. Oral Cavity and mucosal lip (ICD10 C00.3-5, C02-C06)
  3. Malignant melanoma of upper aerodigestive tract (ICD10 C00-06, C09-14, C30-32)
  4. Pharynx (ICD10 C01, C02.4, C05.1-2, C09, C10.0, C10.2-3, C10.9, C11-13)
  5. Salivary glands (ICD10 C00-C14, C15.0, C30-C33, C41.1)
  6. Oesophagus including oesophagogastric junction (ICD10 C15, C16.0)
  7. Gastrointestinal stromal tumours (ICD10 C15-C20, C48.1-2)
  8. Stomach (ICD10 C16 - excluding C16.0)
  9. Small intestine (ICD10 C17)
  10. Appendix (ICD10 C18.1)
  11. Colon and rectum (ICD10 C18-C20)
  12. Anal and perianal skin (ICD10 C21)
  13. Liver (ICD10 C22.0)
  14. Intrahepatic bile ducts (ICD10 C22.1)
  15. Gallbladder (ICD10 C23)
  16. Distal extrahepatic bile duct (ICD10 C24.0)
  17. Perihilar bile ducts (ICD10 C24.0)
  18. Ampulla of vater (ICD10 C24.1)
  19. Pancreas (ICD10 C25)
  20. Nasal cavity and paranasal sinuses (ICD10 C30.0, C31.0, C31.1)
  21. Larynx (ICD10 C32.0, C32.1, C32.2, C10.1)
  22. Lung (ICD10 C34)
  23. Thymus tumours (ICD10 C37.9)
  24. Soft tissues (ICD10 C15-C26, C34-C37 C38.1-3, C47-C49, C51-C53, C58, C60-C68)
  25. Bone (ICD10 C40, C41)
  26. Melanoma of skin (ICD10 C00.0-2, C00.6, C21.2, C43, C51, C60, C63.2)
  27. Merkel cell carcinoma of skin (ICD10 C00, C44, C51, C60, 63.2, C80)
  28. Skin carcinoma of the head and neck (ICD10 C00.0-2, C00.6, C44.0, C44.2-4)
  29. Carcinoma of skin of the eyelid (ICD10 C44.1)
  30. Carcinoma of skin (excluding eyelid, head and neck, perianal, vulva and penis) (ICD10 C44.5-7, C63.2)
  31. Pleural mesothelioma (ICD10 C38.4)
  32. Breast tumours (ICD10 C50)
  33. Vulva (ICD10 C51)
  34. Cervix uteri (ICD10 C53)
  35. Uterine sarcomas
  36. Uterus - endometrium (ICD10 C54.1, C55)
  37. Ovarian, fallopian tube and primary peritoneal carcinoma (ICD10 C56, C57, C48.1, C48.2)
  38. Gestational trophoblastic neoplasms (ICD10 C58)
  39. Penis tumours (ICD10 C60)
  40. Prostate tumours (ICD10 C61.9)
  41. Testis tumours (ICD10 C62)
  42. Kidney tumours (ICD10 C64)
  43. Renal pelvis and ureter tumours (ICD10 C65 & C66)
  44. Urinary bladder tumours (ICD10 C67)
  45. Urethra tumours (ICD10 C68.0, C61.9)
  46. Carcinoma of conjuctiva (ICD10 C69.0)
  47. Melanoma of conjuctiva (ICD10 C69.0)
  48. Retinoblastoma (ICD10 C69.2)
  49. Melanoma of uvea (ICD10 C69.3-4)
  50. Carcinoma of lacrimal gland (ICD10 C69.5)
  51. Sarcoma of orbit (ICD10 C69.6)
  52. Thyroid gland (ICD10 C73.9)
  53. Adrenal cortex (ICD10 C74.0)
  54. Adrenal medulla and extra-adrenal paraganglia (ICD10 C74.1 C75.5)
  55. Parathyroid gland (ICD10 C75.0)
  56. Unknown primary - cervical nodes (ICD10 C77.0)
  57. Mycosis fungoides or sezary syndrome (ICD10 C84.0 and C84.1)
  58. T and B cutaneous lymphoma (ICD10, C82.6, C84.8, C86.6 and other C83-C86 if primary skin excluding C84.0 C84.1)
  59. Rhabdomyosarcoma (CTYA)
  60. Chronic lymphocytic leukaemia
  61. Hepatoblastoma (CTYA)
  62. Hodgkins and non-hodgkins lymphoma (ICD10 C81-88)
  63. Medulloblastoma
  64. Multiple myeloma
  65. Neuroblastoma
  66. Neuroendocrine tumours of the foregut
  67. Neuroendocrine tumours of the midgut and hindgut
  68. Non-hodgkin lymphoma (children)
  69. Wilms tumour of the kidney